NASDAQ:CDNA - CareDx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$31.98 +0.08 (+0.25 %)
(As of 05/24/2019 02:49 PM ET)
Previous Close$31.90
Today's Range$31.60 - $32.40
52-Week Range$10.31 - $39.38
Volume11,191 shs
Average Volume857,614 shs
Market Capitalization$1.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.09
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$76.57 million
Book Value$2.27 per share

Profitability

Net Income$-46,760,000.00

Miscellaneous

Employees227
Market Cap$1.35 billion
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable

CareDx (NASDAQ:CDNA) Frequently Asked Questions

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

How were CareDx's earnings last quarter?

CareDx Inc (NASDAQ:CDNA) posted its earnings results on Wednesday, May, 8th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.03. The company earned $25.98 million during the quarter, compared to analyst estimates of $24.27 million. CareDx had a negative return on equity of 52.93% and a negative net margin of 51.21%. View CareDx's Earnings History.

When is CareDx's next earnings date?

CareDx is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for CareDx.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its FY 2019 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $105-107 million, compared to the consensus revenue estimate of $103.6 million.

What price target have analysts set for CDNA?

5 Wall Street analysts have issued twelve-month price targets for CareDx's stock. Their predictions range from $35.00 to $50.00. On average, they expect CareDx's stock price to reach $42.80 in the next year. This suggests a possible upside of 33.8% from the stock's current price. View Analyst Price Targets for CareDx.

What is the consensus analysts' recommendation for CareDx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.

What are Wall Street analysts saying about CareDx stock?

Here are some recent quotes from research analysts about CareDx stock:
  • 1. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (5/9/2019)
  • 2. HC Wainwright analysts commented, "Our 12-month price target is based on an estimated market value of the firm at $1.83B, which includes a discounted cash flow analysis based asset value for pre- and post-transplant tests, using a 10% discount rate and 2% terminal growth rate, and assuming 43M shares outstanding at the end of 1Q20. Investment risks include: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; and (2) potential dilution risk. CareDx, Inc." (5/9/2019)

Has CareDx been receiving favorable news coverage?

Headlines about CDNA stock have been trending negative this week, according to InfoTrie. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CareDx earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of CareDx's key competitors?

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Square (SQ), Advanced Micro Devices (AMD), Twilio (TWLO), Tandem Diabetes Care (TNDM), Roku (ROKU), Sarepta Therapeutics (SRPT), Cronos Group (CRON), Evolus (EOLS), Intercept Pharmaceuticals (ICPT) and NVIDIA (NVDA).

Who are CareDx's key executives?

CareDx's management team includes the folowing people:
  • Peter K. Maag, Chief Executive Officer & Director
  • Reginald Seeto, President & Chief Business Officer
  • Paul Ciccolella, Senior Vice President-Global Operations
  • Michael Bell, Chief Financial & Principal Accounting Officer
  • James P. Yee, Chief Medical Officer & Executive Vice President

Who are CareDx's major shareholders?

CareDx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.85%), Gagnon Securities LLC (2.60%), Wellington Management Group LLP (1.90%), ArrowMark Colorado Holdings LLC (1.72%), Wells Fargo & Company MN (1.66%) and Goldman Sachs Group Inc. (1.39%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag and Sasha King. View Institutional Ownership Trends for CareDx.

Which institutional investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Royce & Associates LP, Gagnon Advisors LLC, ArrowMark Colorado Holdings LLC, Morgan Stanley, Osterweis Capital Management Inc., Citigroup Inc. and Pier Capital LLC. Company insiders that have sold CareDx company stock in the last year include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag and Sasha King. View Insider Buying and Selling for CareDx.

Which institutional investors are buying CareDx stock?

CDNA stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Redwood Investments LLC, Goldman Sachs Group Inc., Wells Fargo & Company MN, Spark Investment Management LLC, SG Americas Securities LLC, Renaissance Technologies LLC and Geode Capital Management LLC. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $31.98.

How big of a company is CareDx?

CareDx has a market capitalization of $1.35 billion and generates $76.57 million in revenue each year. The company earns $-46,760,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. CareDx employs 227 workers across the globe.

What is CareDx's official website?

The official website for CareDx is http://www.caredxinc.com/.

How can I contact CareDx?

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]


MarketBeat Community Rating for CareDx (NASDAQ CDNA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  532
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel